Patients and tumor specimens
| Patient and specimen ID* . | Patient age (y)† . | Sex . | Clinical stage‡ . | Histologic subtype . |
|---|---|---|---|---|
| CHL, EBV− | ||||
| CHL-1§ | 34 | M | IVB | NS |
| CHL-2§ | 9 | M | IIIB | NS |
| CHL-3§ | 22 | F | IIB | NS |
| CHL-4 | 19 | M | IIIBX | NS |
| CHL-5§ | 47 | F | IVA | NS |
| CHL-6 | 60 | F | IVA | NS |
| CHL-7§ | 60 | F | IIIB | NS |
| CHL-8§ | 13 | F | IVB | NS |
| CHL-9 | 16 | M | IIB | NS |
| CHL-10§ | 15 | M | IIIA | NS |
| CHL-11 | 41 | M | IIB | NS |
| CHL-12§ | 19 | M | IIIB | NS |
| CHL-13§ | 14 | M | IIIAS | NS |
| CHL-14 | 36 | F | IIA | NS |
| CHL-15§ | 16 | F | IA | NS |
| CHL-16§ | 12 | M | IIA | NS |
| CHL-17 | 12 | M | IVA | NS |
| CHL-18 | 50 | M | IIA | NS |
| CHL-19§ | 24 | M | IIIA | NS |
| CHL-20§ | 10 | F | IIIB | NS |
| CHL, EBV+ | ||||
| CHL-21§ | 33 | F | IVB | NS |
| CHL-22§ | 66 | F | IA | NS |
| CHL-23§ | 22 | M | IA | NS |
| CHL-24§ | 10 | M | IIB | NS |
| CHL-25§ | 26 | F | IA | MC |
| CHL-26§ | 25 | M | IVB | MC |
| CHL-27 | 55 | M | IVB | Interfollicular |
| CHL-28 | 19 | M | IIA | Interfollicular |
| CHL-29§ | 21 | F | IIA | NS |
| CHL-30 | 39 | M | IA | MC, recurrent‖ |
| CHL-31 | 52 | M | IIIB | NS, recurrent¶ |
| CHL-32§ | 38 | M | IIA | NS, recurrent# |
| Patient and specimen ID* . | Patient age (y)† . | Sex . | Clinical stage‡ . | Histologic subtype . |
|---|---|---|---|---|
| CHL, EBV− | ||||
| CHL-1§ | 34 | M | IVB | NS |
| CHL-2§ | 9 | M | IIIB | NS |
| CHL-3§ | 22 | F | IIB | NS |
| CHL-4 | 19 | M | IIIBX | NS |
| CHL-5§ | 47 | F | IVA | NS |
| CHL-6 | 60 | F | IVA | NS |
| CHL-7§ | 60 | F | IIIB | NS |
| CHL-8§ | 13 | F | IVB | NS |
| CHL-9 | 16 | M | IIB | NS |
| CHL-10§ | 15 | M | IIIA | NS |
| CHL-11 | 41 | M | IIB | NS |
| CHL-12§ | 19 | M | IIIB | NS |
| CHL-13§ | 14 | M | IIIAS | NS |
| CHL-14 | 36 | F | IIA | NS |
| CHL-15§ | 16 | F | IA | NS |
| CHL-16§ | 12 | M | IIA | NS |
| CHL-17 | 12 | M | IVA | NS |
| CHL-18 | 50 | M | IIA | NS |
| CHL-19§ | 24 | M | IIIA | NS |
| CHL-20§ | 10 | F | IIIB | NS |
| CHL, EBV+ | ||||
| CHL-21§ | 33 | F | IVB | NS |
| CHL-22§ | 66 | F | IA | NS |
| CHL-23§ | 22 | M | IA | NS |
| CHL-24§ | 10 | M | IIB | NS |
| CHL-25§ | 26 | F | IA | MC |
| CHL-26§ | 25 | M | IVB | MC |
| CHL-27 | 55 | M | IVB | Interfollicular |
| CHL-28 | 19 | M | IIA | Interfollicular |
| CHL-29§ | 21 | F | IIA | NS |
| CHL-30 | 39 | M | IA | MC, recurrent‖ |
| CHL-31 | 52 | M | IIIB | NS, recurrent¶ |
| CHL-32§ | 38 | M | IIA | NS, recurrent# |
F, female; M, male; MC, mixed cellularity; NS, nodular sclerosis.
Tumor biopsies were obtained prior to therapy, with the exception of CHL-30, -31, and -32, which were derived from recurrent tumors. All specimens were evaluated with IHC and EBER ISH.
Age at time of biopsy.
According to the modified Ann Arbor staging system.46
Gene expression assessed with qRT-PCR, in 21 specimens from which sufficient material was available.
Recurrent tumor, biopsy obtained 5.5 y after completing multidrug chemotherapy plus radiation therapy.
Recurrent tumor, biopsy obtained 1.7 y after completing combination chemotherapy, rituximab, and tumor vaccine.
Recurrent tumor, biopsy obtained 15 years after completing primary radiation therapy.